Video
Dr. Jean-Yves Blay on Eribulin in Leiomyosarcoma
Author(s):
Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.
Jean-Yves Blay, MD, PhD, professor of medicine at the Université Claude Bernard, Lyon, France, and the scientific director of the Canceropole Lyon Rhône Alpes, discusses a subgroup analysis of leiomyosarcoma patients from a phase III study of eribulin compared to dacarbazine (DTIC) in patients with advanced liposarcoma or leiomysosarcoma.
Leiomyosarcoma is a complex and difficult to treat patient population, says Blay. The analysis found that eribulin was equivalent to DTIC in terms of overall survival and progression-free survival in all subgroups of leiomyosarcoma. This is important because leiomyosarcoma is very heterogeneous, says Blay.
DTIC is well known to be a very active agent in leiomyosarcoma, so the observation that eribulin is equivalent is very interesting for the drug, he says.
Eribulin was well tolerated in leiomyosarcoma patients overall.
